Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Ovarian cancer
drug development
immunotherapy
tumour microenvironment
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
02
2023
revised:
22
05
2023
accepted:
31
05
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance.
Identifiants
pubmed: 37457131
doi: 10.20517/cdr.2023.13
pmc: PMC10344730
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
358-377Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
ADeF declares receiving grant funding from AstraZeneca. All other authors declared that there are no conflicts of interest.
Références
J Clin Oncol. 2009 Mar 20;27(9):1419-25
pubmed: 19224846
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancers (Basel). 2022 Aug 11;14(16):
pubmed: 36010882
J Clin Oncol. 2017 Apr 10;35(11):1240-1249
pubmed: 28221868
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920944116
pubmed: 32782491
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Gynecol Oncol. 2023 Jan;168:23-31
pubmed: 36368129
Ann Oncol. 2021 Jun;32(6):757-765
pubmed: 33667670
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720
pubmed: 28765325
Vaccines (Basel). 2020 Nov 05;8(4):
pubmed: 33167428
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Anticancer Res. 2009 Aug;29(8):2875-84
pubmed: 19661290
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Nat Genet. 2023 Mar;55(3):437-450
pubmed: 36849657
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancers (Basel). 2020 Aug 09;12(8):
pubmed: 32784819
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Clin Cancer Res. 2006 Nov 15;12(22):6808-16
pubmed: 17121902
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Gynecol Oncol. 2008 Mar;108(3):619-26
pubmed: 18222534
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Gynecol Oncol. 2009 Nov;115(2):185-92
pubmed: 19665763
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer. 2000 Jun 1;88(11):2584-9
pubmed: 10861437
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Gynecol Oncol. 2021 Dec;163(3):459-464
pubmed: 34702567
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
Lancet. 2021 Jan 23;397(10271):281-292
pubmed: 33485453
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Clin Med Insights Oncol. 2022 Aug 6;16:11795549221110501
pubmed: 35957960
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Cancer Immunol Immunother. 2010 Jun;59(6):909-19
pubmed: 20087581
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Front Immunol. 2021 Dec 17;12:762989
pubmed: 34975854
Nat Commun. 2013;4:2126
pubmed: 23839242
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Lancet Oncol. 2018 Aug;19(8):1126-1134
pubmed: 30026002
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
JAMA Oncol. 2019 Dec 1;5(12):1731-1738
pubmed: 31600397
Front Immunol. 2022 Jun 27;13:901772
pubmed: 35833132
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
J Immunother Cancer. 2019 Jul 25;7(1):197
pubmed: 31345267
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Theranostics. 2021 Mar 11;11(11):5365-5386
pubmed: 33859752
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Front Oncol. 2014 Apr 02;4:70
pubmed: 24765614
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
JAMA Oncol. 2019 Aug 01;5(8):1141-1149
pubmed: 31194228
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Sci Transl Med. 2022 Jul 6;14(652):eabn1926
pubmed: 35857626
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Nature. 2022 Dec;612(7941):778-786
pubmed: 36517593
Nat Rev Cancer. 2022 Nov;22(11):640-656
pubmed: 36109621
Clin Cancer Res. 2020 Nov 1;26(21):5631-5637
pubmed: 32723836
Gynecol Oncol. 2020 May;157(2):558-559
pubmed: 32087992
Front Oncol. 2020 Oct 22;10:566511
pubmed: 33194645
Clin Cancer Res. 2018 Nov 15;24(22):5685-5696
pubmed: 30065096
Gynecol Oncol. 2011 May 1;121(2):353-7
pubmed: 21324516
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Obstet Gynecol. 2015 Sep;126(3):491-497
pubmed: 26244529
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13
pubmed: 30581539
J Gynecol Oncol. 2022 Jul;33(4):e45
pubmed: 35320892
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Ann Oncol. 2018 Apr 1;29(4):917-923
pubmed: 29401246
Semin Cancer Biol. 2012 Aug;22(4):282-8
pubmed: 22313876
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
J Clin Oncol. 2015 Aug 1;33(22):2457-63
pubmed: 26124480
Nat Genet. 2022 Dec;54(12):1853-1864
pubmed: 36456881
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
Gynecol Oncol. 2010 Mar;116(3):556-62
pubmed: 20006900
Lancet Oncol. 2021 Dec;22(12):1721-1731
pubmed: 34715071
J Clin Oncol. 2021 Nov 20;39(33):3671-3681
pubmed: 34473544
Front Immunol. 2020 May 15;11:940
pubmed: 32499786
Br J Cancer. 1997;76(9):1221-7
pubmed: 9365173